Compare WVE & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | AORT |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.4B |
| IPO Year | 2015 | 1996 |
| Metric | WVE | AORT |
|---|---|---|
| Price | $5.22 | $26.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $29.81 | ★ $49.40 |
| AVG Volume (30 Days) | ★ 3.3M | 730.1K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.62 |
| EPS | N/A | ★ N/A |
| Revenue | $3,704,000.00 | ★ $298,836,000.00 |
| Revenue This Year | N/A | $14.20 |
| Revenue Next Year | $85.67 | $11.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 149.43 | 18.01 |
| 52 Week Low | $5.01 | $19.16 |
| 52 Week High | $21.73 | $48.25 |
| Indicator | WVE | AORT |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 44.42 |
| Support Level | $5.02 | $25.79 |
| Resistance Level | $6.39 | $28.29 |
| Average True Range (ATR) | 0.32 | 1.17 |
| MACD | -0.01 | -0.36 |
| Stochastic Oscillator | 13.57 | 0.00 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.